ASCO 2016

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC

Conference Correspondent - ASCO 2016

Pembrolizumab (pembro) is a humanized anti-PD1 monoclonal antibody approved in the United States for treating PD-L1–expressing advanced non–small-cell lung cancer (NSCLC) that progressed after platinum-based chemotherapy and an approved EGFR or ALK inhibitor. In the phase 3 KEYNOTE-010 study, pembro [ Read More ]

Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status

Conference Correspondent - ASCO 2016

Age and related comorbidities often reduce the therapeutic index of drugs; however, there is no evidence in favor of selecting chemotherapy based on age. Lee and colleagues compared the pemetrexed/carboplatin (PC) doublet versus pemetrexed singlet in chemotherapy-naïve elderly patients aged [ Read More ]